This study will be a double-blind, placebo-controlled, parallel group study. After enrolment
and initial assessments, subjects will receive 35 days of study medication. During this
treatment period, they will be randomised to either oral GW856553 7.5mg BID or matching
placebo in a 1:1 ratio. Sufficient numbers of subjects will be recruited to obtain 128
evaluable subjects.